Bausch & Lomb Corp
BLCONYSE
$16.26
↓ -3.3%Jul 17 close · end-of-day
Price
1Y↑ +16.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$5.8B
Enterprise Value
$10.5B
P/E
—
P/S
1.1
P/B
0.9
EV/EBITDA
16.4
PEG
—
FCF Yield
0.0%
Dividend Yield
—
Revenue (TTM)
$5.2B
Net Income (TTM)
-$219.0M
Free Cash Flow (TTM)
$1.0M
Gross Margin
—
Operating Margin
4.4%
Net Margin
-4.2%
ROE
-3.4%
ROIC
1.6%
Debt / Equity
0.8
Net Cash
-$4.8B
Return 1Y
+14.7%
Company profile
Bausch + Lomb is a leading global eye health company dedicated to protecting and enhancing the gift of sight for millions of people around the world—from the moment of birth through every phase of life.Our business was founded in 1853 and incorporated in the State of New York in 1908 (“Old Bausch + Lomb”). Our executive offices are located at 520 Applewood Crescent, Vaughan, Ontario, Canada.
- CEO
- Joseph C. Papa
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 12,500
- Headquarters
- Ontario
- Website
- bausch.com
Management & directors
- Bonnefoy LucPresident, Surgical
- Saunders Brent LChairman of the Board and CEO
- Eldessouky SamEVP and CFO
- Hashad YehiaEVP of R&D and CMO
- Munsch FrederickSVP, Controller and CAO
- Bailey A Robert DEVP & Chief Legal Officer
- Stewart Andrew J.President, GPIC
Roles derived from SEC Form 4 filings.
Earnings
BLCO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.2B↑ +9.4%
Diluted EPS-$0.20↓ -66.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $3.4B | $3.8B | $3.8B | $4.1B | $4.8B | $5.1B |
| Gross profit | — | — | — | — | — | — |
| Operating income | $260.0M | $329.0M | $207.0M | $130.0M | $162.0M | $113.0M |
| Net income | -$18.0M | $182.0M | $6.0M | -$260.0M | -$317.0M | -$360.0M |
| Diluted EPS | -$0.05 | $0.52 | $0.02 | -$0.74 | -$0.90 | -$1.02 |
| Operating cash flow | $522.0M | $873.0M | $345.0M | -$17.0M | $232.0M | $283.0M |
| Free cash flow | $269.0M | $680.0M | $170.0M | -$198.0M | -$59.0M | -$66.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 7.6% | 8.7% | 5.5% | 3.1% | 3.4% | 2.2% |
| Net margin | -0.5% | 4.8% | 0.2% | -6.3% | -6.6% | -7.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B | $1.2B | $1.3B | $1.1B | $1.3B | $1.3B | $1.4B | $1.2B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $26.0M | $43.0M | $87.0M | -$83.0M | -$11.0M | $95.0M | $112.0M | $33.0M |
| Net income | -$151.0M | $4.0M | -$3.0M | -$212.0M | -$62.0M | -$28.0M | -$58.0M | -$71.0M |
| Diluted EPS | -$0.43 | $0.01 | $0.00 | -$0.60 | -$0.18 | -$0.08 | -$0.16 | -$0.20 |
| Operating cash flow | $15.0M | $154.0M | $22.0M | -$25.0M | $35.0M | $137.0M | $136.0M | $32.0M |
| Free cash flow | -$57.0M | $94.0M | -$70.0M | -$135.0M | -$54.0M | $63.0M | $60.0M | -$68.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 2.1% | 3.6% | 6.8% | -7.3% | -0.9% | 7.4% | 8.0% | 2.7% |
| Net margin | -12.4% | 0.3% | -0.2% | -18.6% | -4.9% | -2.2% | -4.1% | -5.7% |
Company news
Jul 20, 2026
Jul 10, 2026
Jul 9, 2026
- 10d agoBLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failurestocktwits.com
- 11d agoBausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidatefinance.yahoo.com
- 11d agoBausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Carefinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-12 | Bonnefoy Luc· President, Surgical | Tax withholding | 1,008 | $15.08 | $15,200.64 | filing |
| 2026-05-26 | VON ESCHENBACH ANDREW C. | Award | 15,842 | $15.78 | $249,986.76 | filing |
| 2026-05-26 | Ross Thomas W. Sr. | Award | 15,842 | $15.78 | $249,986.76 | filing |
| 2026-05-26 | ROBERTSON RUSSEL C | Award | 15,842 | $15.78 | $249,986.76 | filing |
| 2026-05-26 | Paulson John | Award | 15,842 | $15.78 | $249,986.76 | filing |
| 2026-05-26 | Ling Karen | Award | 15,842 | $15.78 | $249,986.76 | filing |
| 2026-05-26 | KAVANAGH SARAH B | Award | 15,842 | $15.78 | $249,986.76 | filing |
| 2026-05-26 | Bernier Nathalie D. | Award | 15,842 | $15.78 | $249,986.76 | filing |
| 2026-05-26 | Alfonso Eduardo | Award | 15,842 | $15.78 | $249,986.76 | filing |
| 2026-05-26 | COLLIS STEVEN H | Award | 15,842 | $15.78 | $249,986.76 | filing |
| 2026-05-22 | SAUNDERS BRENT L· Chairman of the Board and CEO | Tax withholding | 2,886 | $15.92 | $45,945.12 | filing |
| 2026-05-05 | Eldessouky Sam· EVP and CFO | Tax withholding | 63,938 | $16.00 | $1.0M | filing |
| 2026-05-05 | Hashad Yehia· EVP of R&D and CMO | Tax withholding | 13,664 | $16.00 | $218,624.00 | filing |
| 2026-05-05 | Bonnefoy Luc· President, Surgical | Tax withholding | 11,970 | $16.00 | $191,520.00 | filing |
| 2026-05-05 | Munsch Frederick· SVP, Controller and CAO | Tax withholding | 8,673 | $16.00 | $138,768.00 | filing |
| 2026-04-30 | ROBERTSON RUSSEL C | Award | 1,611 | $15.90 | $25,614.90 | filing |
| 2026-04-30 | COLLIS STEVEN H | Award | 1,415 | $15.90 | $22,498.50 | filing |
| 2026-04-30 | Alfonso Eduardo | Award | 1,375 | $15.90 | $21,862.50 | filing |
| 2026-04-30 | Paulson John | Award | 1,375 | $15.90 | $21,862.50 | filing |
| 2026-04-24 | Bailey A Robert D· EVP & Chief Legal Officer | Tax withholding | 15,806 | $15.82 | $250,050.92 | filing |
| 2026-04-24 | Stewart Andrew J.· President, GPIC | Tax withholding | 4,216 | $15.82 | $66,697.12 | filing |
| 2026-03-06 | SAUNDERS BRENT L· CEO and Chairman of the Board | Buy | 14,700 | $17.14 | $251,958.00 | filing |
| 2026-03-06 | Bailey A Robert D· EVP & Chief Legal Officer | Buy | 14,600 | $17.15 | $250,331.60 | filing |
| 2026-03-06 | Eldessouky Sam· EVP and CFO | Buy | 4,000 | $17.13 | $68,520.00 | filing |
| 2026-03-06 | Eldessouky Sam· EVP and CFO | Award | 4,000 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.